KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 95 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q2 2022. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,987,274 | +691.6% | 287,120 | +541.6% | 0.00% | – |
| Q2 2023 | $630,052 | -39.7% | 44,748 | -53.9% | 0.00% | – |
| Q1 2023 | $1,044,559 | +8.8% | 97,078 | +51.4% | 0.00% | – |
| Q4 2022 | $960,248 | -44.8% | 64,102 | -52.7% | 0.00% | – |
| Q3 2022 | $1,740,000 | +76.3% | 135,500 | +33.0% | 0.00% | – |
| Q2 2022 | $987,000 | +78.2% | 101,900 | +83.0% | 0.00% | – |
| Q1 2022 | $554,000 | -90.9% | 55,668 | -89.2% | 0.00% | – |
| Q4 2021 | $6,080,000 | +68.4% | 516,682 | +63.0% | 0.00% | – |
| Q3 2021 | $3,611,000 | -10.2% | 316,991 | +9.8% | 0.00% | – |
| Q2 2021 | $4,022,000 | -9.8% | 288,713 | +19.9% | 0.00% | – |
| Q1 2021 | $4,459,000 | +2.8% | 240,873 | -1.9% | 0.00% | – |
| Q4 2020 | $4,338,000 | +468.5% | 245,522 | +392.2% | 0.00% | – |
| Q3 2020 | $763,000 | -52.3% | 49,885 | -20.6% | 0.00% | – |
| Q2 2020 | $1,600,000 | – | 62,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |